Bactoclear Holdings

Bactoclear is an Australian biotechnology company focused on developing novel antimicrobial solutions to combat the global challenge of antibiotic resistance. The company's lead research centers on a proprietary combination therapy designed to restore the efficacy of existing antibiotics against resistant bacterial strains, particularly Staphylococcus aureus. By targeting the mechanisms that bacteria use to evade traditional treatments, Bactoclear aims to provide new options for treating chronic wounds and serious skin infections. The company operates primarily in the pre-clinical research phase, leveraging partnerships with Australian research institutions to validate its antimicrobial candidates.